HK1208881A1 - Method for producing soluble fcr as fc-fusion with inert immunoglobulin fc-region and uses thereof fc fc fcr - Google Patents
Method for producing soluble fcr as fc-fusion with inert immunoglobulin fc-region and uses thereof fc fc fcrInfo
- Publication number
- HK1208881A1 HK1208881A1 HK15109569.5A HK15109569A HK1208881A1 HK 1208881 A1 HK1208881 A1 HK 1208881A1 HK 15109569 A HK15109569 A HK 15109569A HK 1208881 A1 HK1208881 A1 HK 1208881A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- fcr
- fusion
- region
- producing soluble
- inert immunoglobulin
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/70535—Fc-receptors, e.g. CD16, CD32, CD64 (CD2314/705F)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12179025 | 2012-08-02 | ||
| PCT/EP2013/066065 WO2014020056A1 (fr) | 2012-08-02 | 2013-07-31 | Procédé pour la production de fcr soluble en tant que fc-fusion avec une fc-région d'immunoglobuline inerte et utilisations de celui-ci |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1208881A1 true HK1208881A1 (en) | 2016-03-18 |
Family
ID=48986096
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK15109569.5A HK1208881A1 (en) | 2012-08-02 | 2015-09-29 | Method for producing soluble fcr as fc-fusion with inert immunoglobulin fc-region and uses thereof fc fc fcr |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US10011644B2 (fr) |
| EP (1) | EP2880170B1 (fr) |
| JP (1) | JP6307077B2 (fr) |
| KR (1) | KR20150038511A (fr) |
| CN (1) | CN104508132B (fr) |
| BR (1) | BR112015002263A2 (fr) |
| CA (1) | CA2876096A1 (fr) |
| DK (1) | DK2880170T3 (fr) |
| ES (1) | ES2602030T3 (fr) |
| HK (1) | HK1208881A1 (fr) |
| HU (1) | HUE029634T2 (fr) |
| MX (1) | MX2015000681A (fr) |
| PL (1) | PL2880170T3 (fr) |
| RU (1) | RU2630659C2 (fr) |
| SG (1) | SG11201408536WA (fr) |
| SI (1) | SI2880170T1 (fr) |
| WO (1) | WO2014020056A1 (fr) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA124083C2 (uk) | 2011-06-28 | 2021-07-21 | ІНГІБРЕКС, Інк. | Злитий серпіновий поліпептид і спосіб його застосування |
| US10400029B2 (en) | 2011-06-28 | 2019-09-03 | Inhibrx, Lp | Serpin fusion polypeptides and methods of use thereof |
| KR20240005109A (ko) * | 2014-10-27 | 2024-01-11 | 인히브릭스, 인크. | 세르핀 융합 폴리펩티드 및 이의 사용 방법 |
| US11566082B2 (en) | 2014-11-17 | 2023-01-31 | Cytiva Bioprocess R&D Ab | Mutated immunoglobulin-binding polypeptides |
| WO2016149109A1 (fr) * | 2015-03-13 | 2016-09-22 | University Of Maryland, Baltimore | Biocapteur à médiation par anticorps universel |
| EP3356829A4 (fr) * | 2015-10-02 | 2019-02-27 | The Macfarlane Burnet Institute For Medical Research And Public Health Ltd | Dosage par liaison et procédé de sondage de fonction d'anticorps avec des multimères de liaison fc |
| US10730908B2 (en) | 2016-05-11 | 2020-08-04 | Ge Healthcare Bioprocess R&D Ab | Separation method |
| US10654887B2 (en) | 2016-05-11 | 2020-05-19 | Ge Healthcare Bio-Process R&D Ab | Separation matrix |
| US10703774B2 (en) | 2016-09-30 | 2020-07-07 | Ge Healthcare Bioprocess R&D Ab | Separation method |
| JP6987424B2 (ja) | 2016-05-11 | 2022-01-05 | サイティバ・バイオプロセス・アールアンドディ・アクチボラグ | 分離マトリックスを洗浄および／または消毒する方法 |
| CN109071613A (zh) | 2016-05-11 | 2018-12-21 | 通用电气医疗集团生物工艺研发股份公司 | 分离基质 |
| JP7106187B2 (ja) | 2016-05-11 | 2022-07-26 | サイティバ・バイオプロセス・アールアンドディ・アクチボラグ | 分離マトリックスを保存する方法 |
| US10889615B2 (en) | 2016-05-11 | 2021-01-12 | Cytiva Bioprocess R&D Ab | Mutated immunoglobulin-binding polypeptides |
| AU2017276706A1 (en) * | 2016-06-07 | 2019-01-03 | Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz-Gemeinschaft | Chimeric antigen receptor and CAR-T cells that bind BCMA |
| CN110267977A (zh) | 2016-08-10 | 2019-09-20 | 亚洲大学校产学协力团 | 细胞因子免疫球蛋白Fc融合异二聚体和包含其的药物组合物 |
| WO2019209995A2 (fr) | 2018-04-25 | 2019-10-31 | Precision Ibd, Inc. | Anticorps anti-tl1a optimisés |
| CA3115680A1 (fr) * | 2018-10-23 | 2020-04-30 | Magenta Therapeutics, Inc. | Conjugues anticorps-medicament (adc) a region fc mise sous silence et utilisations associees |
| TW202033547A (zh) | 2018-10-23 | 2020-09-16 | 美商蜻蜓醫療公司 | 異二聚體fc融合蛋白 |
| KR20220103721A (ko) | 2019-10-24 | 2022-07-22 | 프로메테우스 바이오사이언시즈, 인크. | Tnf 유사 리간드 1a(tl1a)에 대한 인간화 항체 및 그의 용도 |
| GB2595299B (en) | 2020-05-21 | 2022-08-03 | Mabsolve Ltd | Modified immunoglobulin FC regions |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| EP0307434B2 (fr) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Anticorps alteres |
| US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
| JP4124480B2 (ja) | 1991-06-14 | 2008-07-23 | ジェネンテック・インコーポレーテッド | 免疫グロブリン変異体 |
| JP3951062B2 (ja) | 1991-09-19 | 2007-08-01 | ジェネンテック・インコーポレーテッド | 少なくとも遊離のチオールとして存在するシステインを有する抗体フラグメントの大腸菌での発現、２官能性Ｆ（ａｂ’）２抗体の産生のための使用 |
| US5623053A (en) * | 1992-01-10 | 1997-04-22 | California Institute Of Technology | Soluble mammal-derived Fc receptor which binds at a pH ranging from about 5.5 to 6.5 and releases at a pH ranging from about 7.5 to 8.5 |
| AU691811B2 (en) | 1993-06-16 | 1998-05-28 | Celltech Therapeutics Limited | Antibodies |
| US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
| US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
| US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| US6040498A (en) | 1998-08-11 | 2000-03-21 | North Caroline State University | Genetically engineered duckweed |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| EP1068241B1 (fr) | 1998-04-02 | 2007-10-10 | Genentech, Inc. | Variants d'anticorps et fragments de ceux-ci |
| CZ20012406A3 (cs) * | 1999-01-07 | 2002-03-13 | Lexigen Pharmaceuticals, Corp. | Exprese a export proteinů působících proti obezitě jako Fc fúzních proteinů |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| JP4944324B2 (ja) * | 1999-07-13 | 2012-05-30 | ボルダー バイオテクノロジー， インコーポレイテッド | 免疫グロブリン融合タンパク質 |
| CA2385347C (fr) | 1999-10-04 | 2009-12-15 | Medicago Inc. | Methode de regulation de la transcription des genes etrangers |
| US7125978B1 (en) | 1999-10-04 | 2006-10-24 | Medicago Inc. | Promoter for regulating expression of foreign genes |
| JP4351674B2 (ja) | 2002-12-16 | 2009-10-28 | ジェネンテック・インコーポレーテッド | 免疫グロブリン変異体とその使用法およびその使用 |
| US7355008B2 (en) | 2003-01-09 | 2008-04-08 | Macrogenics, Inc. | Identification and engineering of antibodies with variant Fc regions and methods of using same |
| WO2004062619A2 (fr) | 2003-01-13 | 2004-07-29 | Macrogenics, Inc. | Proteines de fusion fc$g(g)r solubles et leurs procedes d'utilisation |
| US20060104968A1 (en) | 2003-03-05 | 2006-05-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases |
| US7871607B2 (en) | 2003-03-05 | 2011-01-18 | Halozyme, Inc. | Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases |
| US7718363B2 (en) | 2003-04-25 | 2010-05-18 | The Kenneth S. Warren Institute, Inc. | Tissue protective cytokine receptor complex and assays for identifying tissue protective compounds |
| TWI353991B (en) | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
| WO2005047327A2 (fr) | 2003-11-12 | 2005-05-26 | Biogen Idec Ma Inc. | Variants de polypeptide se liant au recepteur fc neonatal (fcrn), proteines de liaison fc dimeres et techniques associees |
| CN101124245A (zh) * | 2003-11-12 | 2008-02-13 | 比奥根艾迪克Ma公司 | 新生儿Fc受体(FcRn)-结合多肽变体、二聚体Fc结合蛋白及其相关方法 |
| JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| WO2008091682A2 (fr) | 2007-01-23 | 2008-07-31 | Zymogenetics, Inc. | FCγRIA SOLUBLE ET MÉTHODES ASSOCIÉES |
| US8658766B2 (en) | 2008-06-27 | 2014-02-25 | Zymogenetics, Inc. | Soluble hybrid Fcγ receptors and related methods |
| WO2010048313A2 (fr) | 2008-10-22 | 2010-04-29 | Biogen Idec Ma Inc. | Fcrn recombinants et variants de celui-ci pour une purification de protéines de fusion contenant fc |
| TWI426920B (zh) * | 2010-03-26 | 2014-02-21 | Hoffmann La Roche | 雙專一性、雙價抗－ｖｅｇｆ／抗－ａｎｇ－２抗體 |
-
2013
- 2013-07-31 CA CA2876096A patent/CA2876096A1/fr not_active Abandoned
- 2013-07-31 PL PL13750004T patent/PL2880170T3/pl unknown
- 2013-07-31 RU RU2015104625A patent/RU2630659C2/ru not_active IP Right Cessation
- 2013-07-31 MX MX2015000681A patent/MX2015000681A/es unknown
- 2013-07-31 ES ES13750004.7T patent/ES2602030T3/es active Active
- 2013-07-31 CN CN201380040154.7A patent/CN104508132B/zh active Active
- 2013-07-31 BR BR112015002263A patent/BR112015002263A2/pt not_active IP Right Cessation
- 2013-07-31 HU HUE13750004A patent/HUE029634T2/en unknown
- 2013-07-31 KR KR20157005311A patent/KR20150038511A/ko not_active Application Discontinuation
- 2013-07-31 WO PCT/EP2013/066065 patent/WO2014020056A1/fr active Application Filing
- 2013-07-31 SI SI201330354A patent/SI2880170T1/sl unknown
- 2013-07-31 SG SG11201408536WA patent/SG11201408536WA/en unknown
- 2013-07-31 JP JP2015524773A patent/JP6307077B2/ja active Active
- 2013-07-31 DK DK13750004.7T patent/DK2880170T3/en active
- 2013-07-31 EP EP13750004.7A patent/EP2880170B1/fr active Active
-
2015
- 2015-02-02 US US14/611,645 patent/US10011644B2/en active Active
- 2015-09-29 HK HK15109569.5A patent/HK1208881A1/xx unknown
-
2018
- 2018-06-04 US US15/996,846 patent/US10093714B1/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| SI2880170T1 (sl) | 2016-12-30 |
| CA2876096A1 (fr) | 2014-02-06 |
| JP6307077B2 (ja) | 2018-04-04 |
| US20150140683A1 (en) | 2015-05-21 |
| BR112015002263A2 (pt) | 2017-12-12 |
| JP2015526429A (ja) | 2015-09-10 |
| CN104508132A (zh) | 2015-04-08 |
| US20180265564A1 (en) | 2018-09-20 |
| CN104508132B (zh) | 2017-09-15 |
| US10093714B1 (en) | 2018-10-09 |
| KR20150038511A (ko) | 2015-04-08 |
| HUE029634T2 (en) | 2017-03-28 |
| EP2880170A1 (fr) | 2015-06-10 |
| MX2015000681A (es) | 2015-04-10 |
| SG11201408536WA (en) | 2015-01-29 |
| WO2014020056A1 (fr) | 2014-02-06 |
| RU2630659C2 (ru) | 2017-09-11 |
| EP2880170B1 (fr) | 2016-08-24 |
| RU2015104625A (ru) | 2016-09-20 |
| US10011644B2 (en) | 2018-07-03 |
| PL2880170T3 (pl) | 2017-02-28 |
| DK2880170T3 (en) | 2016-10-24 |
| ES2602030T3 (es) | 2017-02-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1208881A1 (en) | Method for producing soluble fcr as fc-fusion with inert immunoglobulin fc-region and uses thereof fc fc fcr | |
| HK1204627A1 (en) | Anti-fcrn antibodies fcrn | |
| EP2917310A4 (fr) | Procédé pour la fabrication de diesel par oligomérisation | |
| EP3004163A4 (fr) | Procédé pour la purification d'anticorps | |
| LT2698648T (lt) | Važiuojančių transporto priemonių klasifikavimo būdas | |
| HRP20170937T1 (hr) | Postupci za identifikaciju antitijela smanjene imunogenosti | |
| EP2714732A4 (fr) | PROCÉDÉ DE PRÉPARATION DE POLYPEPTIDES CONTENANT Fc À PROPRIÉTÉS AMÉLIORÉES | |
| EP2902817A4 (fr) | Composant optique et procédé pour sa production | |
| EP2894177A4 (fr) | Composition pour matériau optique, et son procédé de production | |
| EP2775305A4 (fr) | Procédé de dosage fluoro-immunologique faisant appel à un complexe polypeptidique contenant une région variable d'anticorps fluoromarquée | |
| EP2889376A4 (fr) | ANTICORPS Fc SPÉCIFIQUE À FcyRII DE SOURIS | |
| EP2875996A4 (fr) | Miroir antireflet, véhicule et procédé de production de miroir antireflet | |
| EP2805803A4 (fr) | Procédé de production d'élément optique et élément optique | |
| IL235994A0 (en) | Humanized anti-trka antibodies with amino acid substitutions | |
| EP2716939A4 (fr) | Véhicule de chantier et procédé de commande de véhicule de chantier | |
| IL240753B (en) | Antibody purification methods | |
| EP2808123A4 (fr) | Procédé d'établissement de structure basée sur la vision | |
| EP2930241A4 (fr) | Nouveau facteur c recombinant et son procédé de production, et procédé pour la mesure d'endotoxine | |
| EP2842969A4 (fr) | Protéine de fusion à base de lactoferrine et son procédé de production | |
| ZA201500228B (en) | Ctla4 fusion proteins for the treatment of diabetes | |
| EP3067367A4 (fr) | Procédé de purification de protéine recombinée | |
| EP2837478A4 (fr) | Produit de vulcanisation et son procédé de production | |
| EP2813206A4 (fr) | Mélange de paraffines et son procédé de production | |
| EP2987801A4 (fr) | Procédé de purification d'une protéine d'anticorps | |
| EP2878471A4 (fr) | Pare-soleil pour automobile |